Breast 

  •  SWOG 1207:  Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy
  • NSABP B-55:  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)
  • BR003 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  • E2112: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  • A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

  • A011502: Double blinded placebo controlled trial of aspirin as adjuvant therapy for node + her2- breast ca

  • CLEE011A2404: Assessing the safety and efficacy of ribociclib in combination with letrozole for the treatment of men and postmenopausal women with HR+, HER2- advanced breast ca with no prior hormonal therapy for advanced disease

  • S1416   Phase II placebo-controlled trial of Cisplatin with or without ABT-888 (Veliparib) in metastatic TNBC and/or BRCA + breast ca

  • EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

  • S1418  A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= Residual Invasive Cancer or Positive Lymph Notes (ypN+) After Neoadjuvant Chemotherapy

For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238.​​​​ or Mia Johnson, RN at 360-788-8240